VOR (Vor Biopharma Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VOR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-26 | RA CAPITAL MANAGEMENT, L.P. | 10%+ Owner | M | — | — |
| 2026-07-21 | Peter Kolchinsky | 10%+ Owner | MIXED | — | — |
| 2026-07-09 | DAVID ZACCARDELLI | Director | A | — | — |
| 2026-06-12 | Daniella Beckman | Director | A | — | — |
| 2026-06-12 | Alexander Cumbo | Director | A | — | — |
| 2026-06-12 | Erez Kalir | Director | A | — | — |
| 2026-06-12 | Andrew David Levin | Director | A | — | — |
| 2026-06-12 | Michel Detheux | Director | A | — | — |
| 2026-06-12 | Fouad Namouni | Director | A | — | — |
| 2026-06-12 | Wouter Joustra | Director | A | — | — |
| 2026-06-12 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2026-04-24 | RA Capital Healthcare Fund LP | Director | Sell | — | — |
| 2026-04-21 | Peter Kolchinsky | Director | Sell | — | — |
| 2026-04-15 | RA Capital Healthcare Fund LP | Director | Sell | — | — |
| 2026-04-10 | Rajeev M. Shah | Director | Sell | — | — |
| 2026-04-06 | Peter Kolchinsky | Director | Sell | — | — |
| 2025-12-19 | Wouter Joustra | Director | A | — | — |
| 2025-12-19 | Andrew David Levin | Director | A | — | — |
| 2025-12-19 | RA Capital Healthcare Fund LP | Director | A | — | — |
| 2025-12-09 | Jean-Paul Kress | CEO and Chairman | MIXED | — | — |
| 2025-12-09 | Qing Che Zuraw | Chief Development Officer | MIXED | — | — |
| 2025-12-09 | Sandesh Mahatme | CFO | D | — | — |
| 2025-10-30 | Peter Kolchinsky | Director | Sell | — | — |
| 2025-10-27 | Rajeev M. Shah | Director | Sell | — | — |
| 2025-10-22 | Rajeev M. Shah | Director | Sell | — | — |
| 2025-10-21 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | — | — |
| 2025-10-17 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | — | — |
| 2025-10-17 | RA Capital Healthcare Fund LP | Director | Sell | — | — |
| 2025-10-15 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-10-10 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | — | — |
| 2025-10-08 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | — | — |
| 2025-10-03 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-09-22 | Peter Kolchinsky | Director | A | — | — |
| 2025-09-18 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-09-15 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-09-10 | Sarah Burgess Reed | Director | A | — | — |
| 2025-09-10 | Peter Kolchinsky | Director | A | — | — |
| 2025-09-10 | Reprogrammed Interchange LLC | 10%+ Owner | Sell | — | — |
| 2025-09-05 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-08-29 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-08-27 | Reid Hoffman | 10%+ Owner | Sell | — | — |
| 2025-07-30 | Qing Che Zuraw | Chief Development Officer | A | — | — |
| 2025-07-18 | Michel Detheux | Director | A | — | — |
| 2025-07-18 | Alexander Cumbo | Director | A | — | — |
| 2025-07-10 | Sandesh Mahatme | CFO | A | — | — |
| 2025-06-27 | Jean-Paul Kress | CEO and Chairman | A | — | — |
| 2025-05-23 | Joshua Resnick | Director | A | — | — |
| 2025-05-23 | Fouad Namouni | Director | A | — | — |
| 2025-05-23 | Matthew R Patterson | Director | A | — | — |
| 2025-05-23 | Sven Ante Lundberg | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,501,882 | — |
| — | Director | 3,936,436 | — |
| — | Director | 2,402,095 | — |
| — | Director | 1,891,036 | — |
| — | 10%+ Owner | 1,333,792 | — |
| — | 10%+ Owner | 1,178,725 | — |
| — | 10%+ Owner | 236,142 | — |
| — | Director | 88,332 | — |
| — | 10%+ Owner | 88,332 | — |
| — | Chief Development Officer | 46,854 | — |
| — | PRESIDENT AND CEO | 45,566 | — |
| — | 10%+ Owner | 14,140 | — |
| — | Chief Sci Off & Head Tech Ops | 10,871 | — |
| — | CHIEF FINANCIAL OFFICER | 9,470 | — |
| — | CHIEF MEDICAL OFFICER | 6,331 | — |
| — | Chief Financial Officer | 2,564 | — |
| — | Vice President of Finance | 2,516 | — |
| — | Director | 1,500 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VOR quote page; the site-wide leaderboard is on the insider transactions hub.